MX2024012263A - Antagonistas/agonistas inversos del receptor cannabinoide 1 y sus usos - Google Patents
Antagonistas/agonistas inversos del receptor cannabinoide 1 y sus usosInfo
- Publication number
- MX2024012263A MX2024012263A MX2024012263A MX2024012263A MX2024012263A MX 2024012263 A MX2024012263 A MX 2024012263A MX 2024012263 A MX2024012263 A MX 2024012263A MX 2024012263 A MX2024012263 A MX 2024012263A MX 2024012263 A MX2024012263 A MX 2024012263A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- disorder
- inverse agonists
- cannabinoid receptor
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328611P | 2022-04-07 | 2022-04-07 | |
| US202363439645P | 2023-01-18 | 2023-01-18 | |
| PCT/US2023/017817 WO2023196556A1 (en) | 2022-04-07 | 2023-04-07 | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012263A true MX2024012263A (es) | 2025-01-09 |
Family
ID=88243528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012263A MX2024012263A (es) | 2022-04-07 | 2024-10-03 | Antagonistas/agonistas inversos del receptor cannabinoide 1 y sus usos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250248973A1 (enExample) |
| EP (1) | EP4504179A4 (enExample) |
| JP (1) | JP2025512995A (enExample) |
| KR (1) | KR20250008741A (enExample) |
| CN (1) | CN119325378A (enExample) |
| AU (1) | AU2023250955A1 (enExample) |
| CA (1) | CA3255170A1 (enExample) |
| GB (1) | GB2633943A (enExample) |
| IL (1) | IL315945A (enExample) |
| MX (1) | MX2024012263A (enExample) |
| WO (1) | WO2023196556A1 (enExample) |
| ZA (1) | ZA202407552B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121816344A (zh) * | 2023-08-21 | 2026-04-07 | 杭州德睿智药科技有限公司 | 用于选择性调节大麻素cb1功能的新型杂环类化合物 |
| WO2025103493A1 (zh) * | 2023-11-16 | 2025-05-22 | 西藏海思科制药有限公司 | 一种大麻素受体1拮抗剂及其应用 |
| WO2025185689A1 (zh) * | 2024-03-08 | 2025-09-12 | 成都轻胜生物医药科技有限公司 | 吡唑衍生物及其用途 |
| CN118580162A (zh) * | 2024-05-27 | 2024-09-03 | 中国药科大学 | 一种酰肼类化合物及无金属策略促进酰肼类化合物制备的方法 |
| US20260092038A1 (en) * | 2024-09-27 | 2026-04-02 | Corbus Pharmaceuticals, Inc. | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003698A3 (cs) * | 2001-03-22 | 2003-06-18 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2012068529A2 (en) * | 2010-11-18 | 2012-05-24 | Jenrin Discovery | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| KR20150113762A (ko) * | 2014-03-31 | 2015-10-08 | 한미약품 주식회사 | 황 작용기를 포함하는 4,5-다이하이드로-1h-피라졸-3-카복스이미드아마이드 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| EP3109237A1 (en) * | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
| WO2020236411A1 (en) * | 2019-05-17 | 2020-11-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase |
-
2023
- 2023-04-07 JP JP2024559421A patent/JP2025512995A/ja active Pending
- 2023-04-07 WO PCT/US2023/017817 patent/WO2023196556A1/en not_active Ceased
- 2023-04-07 GB GB2416413.9A patent/GB2633943A/en active Pending
- 2023-04-07 KR KR1020247036964A patent/KR20250008741A/ko active Pending
- 2023-04-07 AU AU2023250955A patent/AU2023250955A1/en active Pending
- 2023-04-07 CN CN202380045595.XA patent/CN119325378A/zh active Pending
- 2023-04-07 IL IL315945A patent/IL315945A/en unknown
- 2023-04-07 US US18/854,216 patent/US20250248973A1/en active Pending
- 2023-04-07 CA CA3255170A patent/CA3255170A1/en active Pending
- 2023-04-07 EP EP23785417.9A patent/EP4504179A4/en active Pending
-
2024
- 2024-10-03 MX MX2024012263A patent/MX2024012263A/es unknown
- 2024-10-04 ZA ZA2024/07552A patent/ZA202407552B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250248973A1 (en) | 2025-08-07 |
| GB2633943A (en) | 2025-03-26 |
| ZA202407552B (en) | 2025-12-17 |
| WO2023196556A1 (en) | 2023-10-12 |
| EP4504179A4 (en) | 2026-01-07 |
| AU2023250955A1 (en) | 2024-10-17 |
| IL315945A (en) | 2024-11-01 |
| KR20250008741A (ko) | 2025-01-15 |
| GB202416413D0 (en) | 2024-12-25 |
| CA3255170A1 (en) | 2023-10-12 |
| JP2025512995A (ja) | 2025-04-22 |
| EP4504179A1 (en) | 2025-02-12 |
| CN119325378A (zh) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240638A1 (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso | |
| MX2022013619A (es) | Compuestos de 2,4-dioxopirimidina que inhiben cd73. | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| CL2023002204A1 (es) | Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso | |
| EP4361145A4 (en) | Glp-1 receptor agonist and composition and use thereof | |
| MX2022014548A (es) | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). | |
| CR20210562A (es) | Agonistas de glp-1r y usos de los mismos | |
| CO2018012996A2 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| CO2024013569A2 (es) | Moléculas de unión contra frα | |
| ZA202407552B (en) | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | |
| CL2009000090A1 (es) | Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. | |
| BR112019023898A2 (pt) | método para tratamento de câncer gástrico, uso de um anticorpo e composição | |
| CO6362020A2 (es) | Mutantes fgf21 y uso de los mismos | |
| GT200600038A (es) | Agonistas de pyy y sus usos | |
| CL2008002140A1 (es) | Compuestos derivados de azaindol, inhibidores jak; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos proliferativos, cardiacos, neurodegenerativo, asociados con trasplante de organos, artritis reumatoidea, entre otras. | |
| ECSP088543A (es) | Anticuerpos anti-ox40l y métodos que los utilizan | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| DOP2006000219A (es) | Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso | |
| BRPI0504402A (pt) | pistola de adesivo, suporte para um componente adesivo, unidade de mistura, peça de conexão e método de uso da mesma | |
| BRPI0507332A (pt) | aditivo lìquido para trituração intermediária do cimento | |
| CO2026004176A2 (es) | Degradadores de stat6 y usos de los mismos | |
| AR064610A1 (es) | Anticuerpos contra el cd200r | |
| PE20221413A1 (es) | Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas | |
| PE20071364A1 (es) | Procedimiento para tratar perdida de peso no deseada o trastornos alimentarios administrando un agonista de trkb | |
| MX2025004103A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa |